Follow
Mercy Kehinde-Ige
Mercy Kehinde-Ige
Biochemistry & Cancer Biology PhD Student, Georgia Cancer Center, Augusta University
Verified email at augusta.edu
Title
Cited by
Cited by
Year
Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC
LDC Galva, X Jiang, MS Hussein, H Zhang, R Mao, P Brody, Y Peng, ...
Hepatology 76 (2), 330-344, 2022
14*2022
IRF8 Regulates Intrinsic Ferroptosis through Repressing p53 Expression to Maintain Tumor Cell Sensitivity to Cytotoxic T Lymphocytes
DB Poschel, M Kehinde-Ige, JD Klement, D Yang, AD Merting, ...
Cells 12 (2), 310, 2023
32023
Modulated dNTP pools and their influence on DNA repair mechanisms and apoptosis in therapy resistant cancers
D Monroe, M Kehinde-Ige, E Usoro, A Williams, E Steinbeck, S Aycox, ...
Cancer Research 84 (6_Supplement), 1112-1112, 2024
2024
The polyamine-hypusine axis is a promising avenue to improve T-cell metabolism and persistence for adoptive cell therapy
M Kehinde-Ige, O Okoko, G Zhou, H Shi
Cancer Research 84 (6_Supplement), 18-18, 2024
2024
Abstract 1918 Elevated dNTP Pools Synergize with Ionizing Radiation to Impair DNA Damage Repair and Promote Apoptosis in Therapy Resistant Cancers
D Monroe, M Kehinde-Ige, H Shi, W Daddacha
Journal of Biological Chemistry 300 (3), 2024
2024
Abstract 1889 Multi-omic Studies Reveal the Polyamine-Hypusine Axis as a Promising Avenue to Improve T-cell Persistence and Metabolism for Adoptive Cell Therapy
M Kehinde-Ige, O Okoko, G Zhou, H Shi
Journal of Biological Chemistry 300 (3), 2024
2024
Abstract LB036: IRF8 regulates tumor cell sensitivity to intrinsic ferroptosis by repressing p53
D Poschel, M Kehinde-Ige, J Klement, D Yang, A Merting, N Savage, ...
Cancer Research 83 (8_Supplement), LB036-LB036, 2023
2023
Repurposing NSAIDs for chemo-immunotherapy: mechanisms beyond COX inhibition
OD Okoko, MY Gazi, X Wang, C Brandle, M Kehinde-Ige, GA Piazza, ...
Cancer Research 83 (7_Supplement), 6333-6333, 2023
2023
Single-cell flux estimation analysis reveals the metabolic states of tumor-specific CD4+ T cells
M Kehinde-Ige, O Okoko, ZC Ding, G Zhou, H Shi
Cancer Research 83 (7_Supplement), 3693-3693, 2023
2023
Antitumor CD4+ T cells reprogram tumor metabolism to drive progressive tumor regression
C Brandle, OD Okoko, MY Gazi, X Wang, M Kehinde-Ige, H Shi, G Zhou
Cancer Research 83 (7_Supplement), 268-268, 2023
2023
206 Novel intermediate-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against human hepatocellular carcinoma
L Caraballo-Galva, X Jiang, M Hussein, H Zhang, R Mao, P Brody, ...
Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022
2022
Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC
LDC Galva, X Jiang, MS Hussein, H Zhang, R Mao, P Brody, Y Peng, ...
Hepatology 76 (2), 330-344, 2022
2022
Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinoma
Y He, LD Caraballo-Galva, X Jiang, MS Hussein, H Zhang, R Mao, ...
The Journal of Immunology 208 (1_Supplement), 122.22-122.22, 2022
2022
The system can't perform the operation now. Try again later.
Articles 1–13